Revisiting immune exhaustion during HIV infection

Current HIV/AIDS Reports

Volumn 8, Issue 1, 2011, Pages 4-11

  Khaitan, Alka ^a   Unutmaz, Derya ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HIV; Immune activation; LAG 3; PD 1; SIV; T cell exhaustion; Tim 3

Indexed keywords

BIOLOGICAL MARKER; CD38 ANTIGEN; CELL SURFACE PROTEIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INTERLEUKIN 2; LYMPHOCYTE ACTIVATION GENE 3; MEMBRANE PROTEIN; PROGRAMMED DEATH 1 LIGAND 1; T CELL IMMUNOGLOBULIN AND MUCIN DOMAIN CONTAINING MOLECULE 3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; GENE DELETION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LIGAND BINDING; LYMPHOCYTIC CHORIOMENINGITIS; MEMORY T LYMPHOCYTE; MICROARRAY ANALYSIS; MONOCYTE; NATURAL KILLER CELL; PERSISTENT INFECTION; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; UPREGULATION; VIRUS LOAD;

ANIMALS; ANTIGENS, CD; APOPTOSIS REGULATORY PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HIV; HIV INFECTIONS; HUMANS; LYMPHOCYTE ACTIVATION; MEMBRANE PROTEINS; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES;

EID: 79952705605     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-010-0066-0     Document Type: Review

References (55)

1. Lane HC, Masur H, Edgar LC, et al. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1983;309(8):453-8. (Pubitemid 13041485)
2. Hellerstein M, Hanley MB, Cesar D, et al. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1- infected humans. Nat Med. 1999;5(1):83-9. (Pubitemid 29051003)
3. Hazenberg MD, Stuart JW, Otto SA, et al. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood. 2000;95(1):249-55. (Pubitemid 30017249)
4. Valdez H, Lederman MM. Cytokines and cytokine therapies in HIV infection. AIDS Clin Rev. 1997:187-228.
5. Giorgi JV, Liu Z, Hultin LE, et al. Elevated levels of CD38+ CD8 + T cells in HIV infection add to the prognostic value of low CD4 + T cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 1993;6(8):904-12. (Pubitemid 23207458)
6. Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis. 1999;179(4):859-70. (Pubitemid 29159331)
7. Silvestri G, Sodora DL, Koup RA, et al. Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity. 2003;18(3):441-52. (Pubitemid 36351522)
8. Legrand FA, Nixon DF, Loo CP, et al. Strong HIV-1-specific T cell responses in HIV-1-exposed uninfected infants and neonates revealed after regulatory T cell removal. PLoS One. 2006;1:e102. PMCID: 1762312
9. Aandahl EM, Michaelsson J, Moretto WJ, et al. Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol. 2004;78(5):2454-9. PMCID: 369239.
10. Kinter AL, Hennessey M, Bell A, et al. CD25(+)CD4(+) regulatory T cells from the peripheral blood of asymptomatic HIV-infected individuals regulate CD4(+) and CD8(+) HIV-specific T cell immune responses in vitro and are associated with favorable clinical markers of disease status. J Exp Med. 2004;200 (3):331-43. PMCID: 2211981.
11. Weiss L, Donkova-Petrini V, Caccavelli L, et al. Human immunodeficiency virus-driven expansion of CD4+CD25+ regulatory T cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected patients. Blood. 2004;104(10):3249-56. (Pubitemid 39507143)
12. Oswald-Richter K, Grill SM, Shariat N, et al. HIV infection of naturally occurring and genetically reprogrammed human regulatory T-cells. PLoS Biol. 2004;2(7):E198. PMCID: 449855.
13. Eggena MP, Barugahare B, Jones N, et al. Depletion of regulatory T cells in HIV infection is associated with immune activation. J Immunol. 2005;174(7):4407-14. (Pubitemid 40396024)
14. Swiecki M, Colonna M. Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol Rev. 2010;234(1):142-62.
15. El Hed A, Khaitan A, Kozhaya L, et al. Susceptibility of human Th17 cells to human immunodeficiency virus and their perturbation during infection. J Infect Dis. 2010;201(6):843-54. PMCID: 2849315.
16. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12(12):1365-71. (Pubitemid 44924494)
17. Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol. 2003;77(8):4911-27. PMCID: 152117.
18. Wherry EJ, Ha SJ, Kaech SM, et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity. 2007;27(4):670-84. This is the study that identified several markers of immune exhaustion by a microarray analysis of dysfunctional CD8+ T cells during LCMV infection. PD-1 was the most prominent gene identified.
19. Zajac AJ, Blattman JN, Murali-Krishna K, et al. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med. 1998;188(12):2205-13. PMCID: 2212420
20. Urbani S, Amadei B, Tola D, et al. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J Virol. 2006;80(22):11398-403. PMCID: 1642188.
21. Radziewicz H, Ibegbu CC, Fernandez ML, et al. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J Virol. 2007;81(6):2545-53. PMCID: 1865979.
22. Boni C, Fisicaro P, Valdatta C, et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol. 2007;81(8):4215-25. PMCID: 1866111.
23. Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. 2006;443(7109):350-4. This study showed that PD-1 was expressed on HIV-specific CD8+ and CD4+ T cells and correlated with markers of HIV disease progression. HIV-specific CD4+ and CD8+ T-cell responses rescued with blockade of PD-1.
24. Trautmann L, Janbazian L, Chomont N, et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med. 2006;12(10):1198-202. This study showed that PD-1 was upregulated on HIV-specific but not CMV-specific CD8+ T cells and correlated with markers of HIV disease progression. Blocking PD-1 resulted in enhanced survival, proliferation, and cytokine secretion by HIV-specific CD8+ T cells.
25. El-Far M, Halwani R, Said E, et al. T-cell exhaustion in HIV infection. Curr HIV/AIDS Rep. 2008;5(1):13-9. (Pubitemid 351480776)
26. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11(11):3887-95. PMCID: 556898.
27. Kaufmann DE, Walker BD. Programmed death-1 as a factor in immune exhaustion and activation in HIV infection. Curr Opin HIV AIDS. 2008;3(3):362-7. (Pubitemid 351521022)
28. Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11(2):141-51. (Pubitemid 29428807)
29. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007;8(3):239-45.
30. Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439(7077):682-7. This study reported that T-cell exhaustion mediated by PD-1 was reversible by in vitro blockade of PD-1 in the murine LCMV model.
31. Monney L, Sabatos CA, Gaglia JL, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002;415(6871):536-41. (Pubitemid 34130609)
32. Zhu C, Anderson AC, Schubart A, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;6(12):1245-52. (Pubitemid 43045636)
33. Sabatos CA, Chakravarti S, Cha E, et al. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol. 2003;4(11):1102-10. (Pubitemid 37428038)
34. Hafler DA, Kuchroo V. TIMs: central regulators of immune responses. J Exp Med. 2008;205(12):2699-701. PMCID: 2585854
35. Hastings WD, Anderson DE, Kassam N, et al. TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines. Eur J Immunol. 2009;39(9):2492-501. PMCID: 2759376. This report was the first to demonstrate Tim-3 is a negative regulator of Th1 and Th17 cells. They showed Tim-3 was expressed on activated Th17 cells in addition to Th1 cells. Activated CD4+ T cells cultured with monoclonal antibodies to Tim-3 increased IL-17, IFNγ, IL-2, and IL-6 but not Il-10 secretion.
36. Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. Immunol Rev. 2008;223:87-113. (Pubitemid 351986173)
37. Durelli L, Conti L, Clerico M, et al. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann Neurol. 2009;65(5):499-509.
38. Koguchi K, Anderson DE, Yang L, et al. Dysregulated T cell expression of TIM3 in multiple sclerosis. J Exp Med. 2006;203 (6):1413-8. PMCID: 2118310.
39. Blackburn SD, Shin H, Haining WN, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2009;10(1):29-37. PMCID: 2605166. This report demonstrates that exhausted T cells coexpress multiple negative regulators and coexpression is associated with more severe T-cell exhaustion and infection. Dual blockade of PD-1 and LAG-3 synergistically improved CD8+ T-cell function and lowered viral load in the LCMV murine model.
40. Richter K, Agnellini P, Oxenius A. On the role of the inhibitory receptor LAG-3 in acute and chronic LCMV infection. Int Immunol. 2010;22(1):13-23. This review discusses the role of LAG-3 during LCMV infection.
41. Romagnani S. Th1 and Th2 in human diseases. Clin Immunol Immunopathol. 1996;80(3 Pt 1):225-35.
42. Zhang JY, Zhang Z, Wang X, et al. PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors. Blood. 2007;109(11):4671-8. (Pubitemid 46827757)
43. Petrovas C, Price DA, Mattapallil J, et al. SIV-specific CD8+ T cells express high levels of PD1 and cytokines but have impaired proliferative capacity in acute and chronic SIVmac251 infection. Blood. 2007;110(3):928-36. PMCID: 1924769. This study demonstrated the in vivo relevance of PD-1 in the non-human primate model of SIV infection. SIV-specific CD8+ T cells with high levels of PD-1 expression had low proliferative capacity compared with PD-1(low) T cells. SIV epitopes with mutational escapes led to decreased PD-1 expression, showing that repeated TCR stimulation is a crucial factor in PD-1 expression.
44. Velu V, Kannanganat S, Ibegbu C, et al. Elevated expression levels of inhibitory receptor programmed death 1 on simian immunodeficiency virus-specific CD8 T cells during chronic infection but not after vaccination. J Virol. 2007;81(11):5819-28. PMCID: 1900286. During SIV infection in macaques, this study reports the majority of SIV-specific CD8+ T cells express PD-1. Levels of PD-1 were highest in the lymph nodes and rectal mucosa and correlated with plasma viremia. They also showed that in vitro blockade of PD-1 enhanced SIV-specific CD8+ and CD4+ T-cell proliferation.
45. Velu V, Titanji K, Zhu B, et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature. 2009;458 (7235):206-10. PMCID: 2753387. This was the first in vivo trial of the safety and immune restoration potential of PD-1 blockade in macaques with chronic SIV infection. PD-1 blockade was well tolerated by macaques and resulted in rapid expansion of HIV-specific CD8+ T cells with improved polyfunctionality, thus establishing both safety and efficacy of PD-1 blockade in the SIV/macaque model.
46. Estes JD, Gordon SN, Zeng M, et al. Early resolution of acute immune activation and induction of PD-1 in SIV-infected sooty mangabeys distinguishes nonpathogenic from pathogenic infection in rhesus macaques. J Immunol. 2008;180(10):6798-807. PMCID: 2596686.
47. Said EA, Dupuy FP, Trautmann L, et al. Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection. Nat Med. 2010;16(4):452-9. In this study the authors demonstrate that PD-L1 triggering of PD-1 expressed on monocytes induced IL-10 production and reversible CD4+ T-cell dysfunction. They also show that HIV-infected individuals have high PD-1 expression on monocytes, which may be triggered by products of microbial translocation.
48. Jones RB, Ndhlovu LC, Barbour JD, et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med. 2008;205(12):2763-79.PMCID: 2585847. This was the first study of Tim-3 in HIV-infected individuals, showing elevated levels of Tim-3 on CD8+ T cells in HIV+ individuals that correlated with CD4+ T cells and HIV viral load. Blockade of Tim-3 resulted in improved HIV-specific CD8+ T-cell responses.
49. Price P, Keane N, Gray L, et al. CXCR4 or CCR5 tropism of human immunodeficiency virus type 1 isolates does not determine the immunological milieu in patients responding to antiretroviral therapy. Viral Immunol. 2006;19(4):734-40. (Pubitemid 46068066)
50. Lim AY, Price P, Beilharz MW, French MA. Cell surface markers of regulatory T cells are not associated with increased forkhead box p3 expression in blood CD4+ T cells from HIV-infected patients responding to antiretroviral therapy. Immunol Cell Biol. 2006;84(6):530-6. (Pubitemid 44657025)
51. Antonelli LR, Mahnke Y, Hodge JN, et al. Elevated frequencies of highly activated CD4+ T cells in HIV+ patients developing immune reconstitution inflammatory syndrome. Blood. 2010. This report demonstrated that in HIV-infected individuals initiating antiretroviral therapy, those who developed immune reconstitution syndrome had higher baseline levels of PD-1 with CTLA-4 and LAG-3 coexpression on CD4+ T cells.
52. Jin HT, Anderson AC, Tan WG, et al. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc Natl Acad Sci USA 2010;107(33):14733-8. In this study, the authors evaluate Tim-3 and PD-1 coexpression during LCMV infection in the mouse, showing PD-1+Tim-3+ CD8+ T cells had more severe T-cell exhaustion. Combined inhibition of PD-1 and Tim-3 synergistically improved CD8+ T-cell responses.
53. Vali B, Jones RB, Sakhdari A, et al. HCV-specific T cells in HCV/ HIV co-infection show elevated frequencies of dual Tim-3/PD-1 expression that correlate with liver disease progression. Eur J Immunol. 2010.
54. Sachdeva M, Fischl MA, Pahwa R, et al. Immune exhaustion occurs concomitantly with immune activation and decrease in regulatory T cells in viremic chronically HIV-1-infected patients. J Acquir Immune Defic Syndr. 2010;54(5):447-54.
55. Vollbrecht T, Brackmann H, Henrich N, et al. Impact of changes in antigen level on CD38/PD-1 co-expression on HIV-specific CD8 T cells in chronic, untreated HIV-1 infection. J Med Virol. 2010;82(3):358-70.